GBS drug trial pulled before it even started
NCT ID NCT05701189
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aimed to test the safety and effectiveness of efgartigimod in people with Guillain-Barre syndrome (GBS), a rare nerve disorder causing weakness. Participants would have received the drug alongside standard care and undergone blood tests and surveys. However, the trial was withdrawn before enrolling anyone, so no results are available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GUILLAIN-BARRE SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hospital of University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.